Results 101 to 110 of about 68,907 (308)

Fixed Eruptions: Drug, food, and what more?

Clinical Dermatology Review
Fixed drug eruption (FDE) is a common entity encountered in our day-to-day clinical practice. It is a T-cell-dependent pathway with induction of interferon-gamma-producing CD8+ T-cells in the dermis and epidermis.
Prabhakar Mallikarjuna Sangolli, Neethu Mary George   +1 more
doaj   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Global Perspectives on Kava: A Narrative Systematic Review of the Health Effects, Economic and Social Impacts and Policy Considerations

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction Kava is a plant‐based drug central to many Pacific Island cultures, yet its physiological and psychological effects remain contested and poorly understood. Additionally, the broader social, economic, and policy consequences of kava trade and consumption are unclear.
George Economidis, Michelle Lynch, Sophia Taylor, Winifred Asare‐Doku, Georgina Macpherson, Louisa Degenhardt, Michael Farrell, Thomas Santo Jr   +7 more
wiley   +1 more source

Fixed Drug Eruption Due to Allopurinol: Positive Oral Provocation [PDF]

, 2011
A fixed drug eruption (FDE) is characterized by the presence of a solitary or multiple, pruritic, well-circumscribed, erythematous plaques. These lesions have tendency to recur at same sites and heal with residual hyperpigmenation. With repeated attacks,
Hei Sung Kim, Hyun Jong Lee, Hyung Ok Kim, Jun Young Lee, Lee, Lee, Shiohara, Tsai, Young Min Park, Zedlitz   +9 more
core   +3 more sources

International survey of treatment practices for atopic dermatitis in pregnant and breastfeeding women: Physician perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Systemic treatment of pregnant/breastfeeding atopic dermatitis (AD) patients is challenging due to limited safety data. We explored treatment practices with systemic agents, including the guideline‐recommended cyclosporine as the first systemic choice as well as emerging therapies, in this vulnerable population ...
Manuel P. Pereira, Katarina Stevanovic, Emek Kocatürk, Cathrin Meesch, Ingrid van Hofman, Prema S. Vaswani, Jonathan A. Bernstein, Dayanne Bruscky, Herberto J. Chong‐Neto, Chia‐Yu Chu, Roberta Fachini Jardim Criado, Luis Felipe Ensina, Ana M. Giménez‐Arnau, Kiran Godse, Maia Gotua, Stamatios Gregoriou, Kanokvalai Kulthanan, Charlotte G. Mortz, Natasa Teovska Mitrevska, Esen Özkaya, Prajwal Pudasaini, Mara Morelo Rocha Felix, Catalina Rincón Pérez, Claudio Alberto Salvador Parisi, Gonzalo N. Ramón, Efstratios Vakirlis, Zuotao Zhao, Lisa A. Beck, Marjolein de Bruin‐Weller, Michael Cork, Norito Katoh, Thomas Werfel, Margitta Worm, Andreas Wollenberg, Torsten Zuberbier   +34 more
wiley   +1 more source

A possible case of etoricoxib induced fixed drug eruption [PDF]

, 2019
Fixed drug eruption (FDE) is a most commonly with adverse drug reaction seen with use of Non-steroidalanti-inflammatory drugs (NSAIDs) in particular nimesulide followed by antibiotics and anticonvulsants.
., Apoorva, K., Girish, Manjunath, Namrata C.   +2 more
core   +2 more sources

A clinical study of morphological patterns of cutaneous adverse drug reaction and its causality assessment in tertiary care hospital of central India [PDF]

, 2020
Background: Adverse reactions to drugs are as old as drug. Cutaneous adverse drug reactions are the most common type of drug reaction. Most cutaneous adverse drug reactions are important as they are frequently the reason for discontinuation of drug ...
Shende, Tanaji R., Siddiqui, Riyaz A.
core   +2 more sources

Novel and recurrent histopathologic patterns of mogamulizumab‐associated rash: diagnostic implications and insights for accurate diagnosis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Mogamulizumab‐associated rash (MAR) is a frequent side‐effect of a treatment with Mogamulizumab that poses diagnostic challenges. Patients and methods We reviewed our database for novel histological patterns in MAR. Results Four new histological patterns were identified: (1) A pagetoid pattern, which could be mistaken for CD8 ...
Christina Mitteldorf
wiley   +1 more source

A case of generalized bullous fixed drug eruptions induced by ceftriaxone [PDF]

Fixed drug eruption (FDE) is a delayed-type hypersensitivity reaction to a systemic medication. Generalized bullous fixed drug eruption (GBFDE) is a rare variant involving generalized bullae and erosions across multiple anatomical sites.
Kanjariya, Dilip, Rathva, Trushti, Sinha, Anita, Solanki, Vaibhav   +3 more
core   +2 more sources

Maximal Points of Head's Zone in Fixed Drug Eruption [PDF]

, 2011
The principles determining the primary localization of lesions in fixed drug eruption (FDE) are still unknown. Studies investigating the predilection areas in FDE have indicated drug-related, trauma-related, or inflammation-related specific site ...
Dong Kyun Hong, Hansen, Hauser, Jeung Hoon Lee, Kanwar, Korkij, Lett, Mizukawa, Mizukawa, Myung Im, Ozkaya, Ozkaya-Bayazit, Sang Sin Lee, Sehgal, Sharma, Shiohara, Shiohara, Stüttgen, Teraki, Thankappan, Young Joon Seo, Young Lee   +21 more
core   +2 more sources